Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
36.34
-0.26 (-0.72%)
At close: Apr 28, 2026, 4:00 PM EDT
36.34
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Cogent Biosciences Employees
Cogent Biosciences had 258 employees as of December 31, 2025. The number of employees increased by 53 or 25.85% compared to the previous year.
Employees
258
Change (1Y)
53
Growth (1Y)
25.85%
Revenue / Employee
n/a
Profits / Employee
-$1,274,950
Market Cap
5.85B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,846 |
| PTC Therapeutics | 991 |
| Rhythm Pharmaceuticals | 414 |
| Immunovant | 362 |
| Apogee Therapeutics | 261 |
| Celcuity | 155 |
| CG Oncology | 142 |
| Centessa Pharmaceuticals | 118 |
COGT News
- 7 days ago - Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 11 days ago - Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 - GlobeNewsWire
- 27 days ago - Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) - GlobeNewsWire
- 6 weeks ago - Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) - GlobeNewsWire
- 6 weeks ago - Cogent Biosciences Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting - GlobeNewsWire
- 2 months ago - Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting - GlobeNewsWire